ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2022
Ocular Nanomedicine.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Potential of Nanoparticle-Based Phototherapies for Future Treatment of Uveal Melanoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Light-Triggered and Sustained Delivery of Dexamethasone Using Chitosan-Coated PLGA Nanoparticles for Posterior Eye Disease Treatment.ACS omega · 2026Article
- Review
- Protamine nanocapsules as gene delivery carriers for the treatment of intraocular tumors.Drug delivery and translational research · 2026Article
- Advancing regenerative medicine with RNA nanotechnology for chronic and end organ diseases.Communications medicine · 2026Review
- Nanotechnology for the Treatment of Radiation Dermatitis: Advances and Translational Perspectives.International journal of nanomedicine · 2026Review
- Nanomaterial-enabled delivery of plant-derived bioactive metabolites for diabetic retinopathy: from evidence appraisal to preclinical translation.Frontiers in pharmacology · 2026Review
- Innovative Applications of Nanomaterials in the Diagnosis and Treatment of Ocular Diseases: Targeted Delivery, Intelligent Therapy, Diagnostic Breakthroughs, and Synergistic Strategies with Stem Cells and Biomaterials.International journal of nanomedicine · 2026Review
- Latest Advancements in Biotherapeutics.Current pharmaceutical biotechnology · 2026Article
- Recent Progress in Selenium Nanomedicines for Ocular Diseases.International journal of nanomedicine · 2026Review
- Targeting Ocular Tissue through Surface-Modified and Multifunctional Biomaterials and mRNA-Based Therapeutics.Current pharmaceutical design · 2026Review
- Inorganic nanomaterials as promising therapeutic agents for ocular neovascularization: Progress and perspectives.Materials today. Bio · 2025Review
- Nanomedicine-Based Treatments for Rare and Aggressive Ocular Cancers: Advances in Drug Delivery.Current treatment options in oncology · 2025Review
- Mitochondria in oxidative stress, inflammation and aging: from mechanisms to therapeutic advances.Signal transduction and targeted therapy · 2025Review
- Ocular drug delivery systems based on nanotechnology: a comprehensive review for the treatment of eye diseases.Discover nano · 2025Review
- Frontier applications of retinal nanomedicine: progress, challenges and perspectives.Journal of nanobiotechnology · 2025Review
- Nanomedicine-Based Ophthalmic Drug Delivery Systems for the Treatment of Ocular Diseases.International journal of nanomedicine · 2025Review
- Recent advances in photothermal nanomaterials for ophthalmic applications.Beilstein journal of nanotechnology · 2025Review
- Innovative Nanotechnology in Drug Delivery Systems for Advanced Treatment of Posterior Segment Ocular Diseases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Recent Advances in Nanomedicine for Ocular Fundus Neovascularization Disease Management.Advanced healthcare materials · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Intrinsic shortcomings associated with conventional therapeutic strategies often compromise treatment efficacy in clinical ophthalmology, prompting the rapid development of versatile alternatives for satisfactory diagnostics and therapeutics. Given advances in material science, nanochemistry, and nanobiotechnology, a broad spectrum of functional nanosystems has been explored to satisfy the extensive requirements of ophthalmologic applications. In the present review, the recent progress in nanosystems, both conventional and emerging nanomaterials in ophthalmology from state-of-the-art studies, are comprehensively examined and the role of their fundamental physicochemical properties in bioavailability, tissue penetration, biodistribution, and elimination after interacting with the ophthalmologic microenvironment emphasized. Furthermore, along with the development of surface engineering of nanomaterials, emerging theranostic methodologies are promoted as potential alternatives for multipurpose ocular applications, such as emerging biomimetic ophthalmology (e.g., smart electrochemical eye), thus provoking a holistic review of "ocular nanomedicine." By affording insight into challenges encountered by ocular nanomedicine and further highlighting the direction of future studies, this review provides an incentive for enriching ocular nanomedicine-based fundamental research and future clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.